NZ592641A - 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine, its salts, and uses in medical treatment - Google Patents

3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine, its salts, and uses in medical treatment

Info

Publication number
NZ592641A
NZ592641A NZ592641A NZ59264109A NZ592641A NZ 592641 A NZ592641 A NZ 592641A NZ 592641 A NZ592641 A NZ 592641A NZ 59264109 A NZ59264109 A NZ 59264109A NZ 592641 A NZ592641 A NZ 592641A
Authority
NZ
New Zealand
Prior art keywords
methyl
morpholinomethyl
pyridazin
fluorobenzyl
imidazo
Prior art date
Application number
NZ592641A
Other languages
English (en)
Inventor
Timothy Paul Burkholder
Joshua Ryan Clayton
Liandong Ma
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41630090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ592641(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ592641A publication Critical patent/NZ592641A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ592641A 2008-12-16 2009-12-08 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine, its salts, and uses in medical treatment NZ592641A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16
PCT/US2009/067056 WO2010074947A1 (en) 2008-12-16 2009-12-08 Amino pyrazole compound

Publications (1)

Publication Number Publication Date
NZ592641A true NZ592641A (en) 2013-01-25

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ592641A NZ592641A (en) 2008-12-16 2009-12-08 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine, its salts, and uses in medical treatment

Country Status (38)

Country Link
US (2) US7897600B2 (enExample)
EP (1) EP2379557B1 (enExample)
JP (1) JP5509217B2 (enExample)
KR (1) KR101300458B1 (enExample)
CN (1) CN102232075B (enExample)
AR (1) AR074240A1 (enExample)
AU (1) AU2009330503B2 (enExample)
BR (1) BRPI0923048A2 (enExample)
CA (1) CA2744714C (enExample)
CL (1) CL2011001445A1 (enExample)
CO (1) CO6331442A2 (enExample)
CR (1) CR20110341A (enExample)
CY (1) CY1113637T1 (enExample)
DK (1) DK2379557T3 (enExample)
DO (1) DOP2011000190A (enExample)
EA (1) EA019554B1 (enExample)
EC (1) ECSP11011132A (enExample)
ES (1) ES2396617T3 (enExample)
HN (1) HN2011001697A (enExample)
HR (1) HRP20120918T1 (enExample)
IL (1) IL213065A0 (enExample)
JO (1) JO2833B1 (enExample)
MA (1) MA32900B1 (enExample)
MX (1) MX2011006441A (enExample)
MY (1) MY158691A (enExample)
NZ (1) NZ592641A (enExample)
PA (1) PA8851101A1 (enExample)
PE (1) PE20110549A1 (enExample)
PL (1) PL2379557T3 (enExample)
PT (1) PT2379557E (enExample)
SG (1) SG172202A1 (enExample)
SI (1) SI2379557T1 (enExample)
SV (1) SV2011003949A (enExample)
TN (1) TN2011000292A1 (enExample)
TW (1) TWI440640B (enExample)
UA (1) UA104743C2 (enExample)
WO (1) WO2010074947A1 (enExample)
ZA (1) ZA201103942B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
US9127074B2 (en) * 2011-03-07 2015-09-08 Fondazione Telethon TFEB variants and uses thereof
JP6228113B2 (ja) * 2011-06-15 2017-11-08 ライフ・アンド・ブレイン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＬＩＦＥ ＡＮＤ ＢＲＡＩＮ ＧｍｂＨ グリア芽腫阻害化合物およびその使用
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
DK3179992T3 (da) 2014-08-11 2022-07-11 Acerta Pharma Bv Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor
DK3179991T3 (da) 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
KR102611856B1 (ko) * 2016-11-17 2023-12-07 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn-알파의 이미다조피리다진 조정제
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2003002825A0 (en) 2000-12-21 2003-09-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
CN1596255A (zh) 2001-12-21 2005-03-16 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物
PL1853588T3 (pl) 2005-02-16 2008-11-28 Astrazeneca Ab Związki chemiczne
SI1853602T1 (sl) 2005-02-16 2010-11-30 Astrazeneca Ab Kemične spojine
AU2006265840B2 (en) * 2005-07-01 2010-02-11 Irm Llc Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
US7776865B2 (en) * 2005-10-06 2010-08-17 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
TWI333953B (en) * 2005-10-06 2010-12-01 Schering Corp Pyrazolopyrimidines as protein kinase inhibitors
AU2006320580B2 (en) 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
WO2008052734A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
CN101679412A (zh) 2007-05-23 2010-03-24 药典有限责任公司 作为PKC-θ抑制剂的嘌呤酮类和1H-咪唑并吡啶酮类
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Also Published As

Publication number Publication date
TW201024301A (en) 2010-07-01
BRPI0923048A2 (pt) 2018-09-25
EA201170831A1 (ru) 2011-12-30
EA019554B1 (ru) 2014-04-30
DOP2011000190A (es) 2011-07-31
ES2396617T3 (es) 2013-02-22
AR074240A1 (es) 2011-01-05
CA2744714C (en) 2013-06-25
SI2379557T1 (sl) 2013-02-28
PA8851101A1 (es) 2010-07-27
MA32900B1 (fr) 2011-12-01
SV2011003949A (es) 2011-07-21
ZA201103942B (en) 2012-08-29
TN2011000292A1 (en) 2012-12-17
CY1113637T1 (el) 2016-06-22
IL213065A0 (en) 2011-07-31
KR101300458B1 (ko) 2013-08-30
US20100286139A1 (en) 2010-11-11
MX2011006441A (es) 2011-07-19
CR20110341A (es) 2011-07-13
US20100152181A1 (en) 2010-06-17
JO2833B1 (en) 2014-09-15
AU2009330503B2 (en) 2012-06-07
EP2379557A1 (en) 2011-10-26
HK1160109A1 (en) 2012-08-10
HN2011001697A (es) 2013-11-26
SG172202A1 (en) 2011-07-28
AU2009330503A1 (en) 2010-07-01
EP2379557B1 (en) 2012-10-31
CO6331442A2 (es) 2011-10-20
DK2379557T3 (da) 2012-12-17
PL2379557T3 (pl) 2013-03-29
WO2010074947A1 (en) 2010-07-01
MY158691A (en) 2016-10-31
JP2012512158A (ja) 2012-05-31
CN102232075B (zh) 2013-12-11
PE20110549A1 (es) 2011-08-04
PT2379557E (pt) 2013-01-14
CN102232075A (zh) 2011-11-02
TWI440640B (zh) 2014-06-11
ECSP11011132A (es) 2011-07-29
KR20110084993A (ko) 2011-07-26
US7897600B2 (en) 2011-03-01
UA104743C2 (ru) 2014-03-11
CL2011001445A1 (es) 2011-11-11
CA2744714A1 (en) 2010-07-01
JP5509217B2 (ja) 2014-06-04
HRP20120918T1 (hr) 2012-12-31

Similar Documents

Publication Publication Date Title
NZ592641A (en) 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine, its salts, and uses in medical treatment
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
MY164705A (en) Imidazo [4,5-c] quinolin - 2 - one compound and its use as pi3 kinase / mtor dual inhibitor
UA103792C2 (uk) Похідна бензодіазепіну для лікування гемопоетичної неоплазми та лейкозу
MX2010009458A (es) Derivados biciclicos heterociclicos o espirobiciclicos heterociclicos enlazados, de pirazolo[1,5-a]pirimidinas, procedimientos para su preparacion y usos de los mismos.
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MX2019013643A (es) Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona.
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
EP4249076A3 (en) (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor
MX2010009414A (es) Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met.
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
ZA201206715B (en) Imidazo [1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological,psychiatric and metabolic disorders and diseases
WO2009007748A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
JP2012524089A5 (enExample)
EA200800992A1 (ru) 2-амино-7,8-дигидро-6н-пиридо[4,3-d]пиримидин-5-оны, способ их получения, способ терапии с их помощью, компонент композиции и композиция на их основе, 2,4-диоксопиперидиновые соединения для их получения
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
MX2010014230A (es) Composiciones que contienen pirido [2,3-d] pirimidinas sustituidas con metilmorfolina y proceso relacionado.
MX390132B (es) 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
MX2012001529A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-piridazin-6-ilo como moduladores de cinasa de tirosina c-met.
TW200806301A (en) Combination therapy of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-YL)-1-OXO-2,6-dihydro-1H-[1,2]diazepino[4,5,6-CD]indol-8-YL)acetamide
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
WO2014186388A3 (en) Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 DEC 2016 BY THOMSON REUTERS

Effective date: 20130920

LAPS Patent lapsed